Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus: The AleCardio Randomized Clinical Trial

Study Questions:

What is the impact of the dual peroxisome proliferator-activated receptor agonist (aleglitazar) on the risk of cardiovascular morbidity and mortality among patients with diabetes mellitus and recent acute coronary syndrome (ACS)?